Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.
In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting. The company offers training and technical support to hospital laboratories and specialty clinics, ensuring that staff are properly instructed in isotope handling, system operation and result interpretation. Through ongoing research collaborations, Daxor continuously evaluates new protocols and software enhancements to improve diagnostic performance and workflow efficiency.
Headquartered in New York, Daxor serves healthcare providers in North America and has established distribution partnerships in Europe, Asia‐Pacific and select emerging markets. Its solutions are used by major university medical centers, community hospitals and research institutions to inform decisions on blood transfusion, fluid management and therapeutic intervention. The company’s management team brings decades of experience in medical technology commercialization, regulatory affairs and laboratory operations, positioning Daxor to expand its global footprint and address evolving needs in patient blood management.
AI Generated. May Contain Errors.
Free DXR Stock Alerts